Healthcare Industry News: drug-eluting stent
News Release - September 13, 2010
Tryton Announces Launch in Several European and Eastern European CountriesExcellent Six-Month Clinical Results with Target Lesion Revascularization Rate of Less Than Four Percent
DURHAM, N.C.--(Healthcare Sales & Marketing Network)--Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the company has launched the Tryton Stent System in Switzerland, Sweden, Finland, Turkey, Hungary, Czech Republic, Slovakia and Latvia.
“We are pleased to expand availability of the Tryton Stent System to additional countries in Europe and Eastern Europe, broadening our reach and bringing the Tryton solution to many more patients and clinicians,” said J. Greg Davis, president and CEO of Tryton Medical.
“I have been very pleased with my experience with the Tryton Stent, which provides a simple solution to a highly complex clinical problem,” said Imre Ungi, M.D., Ph.D., associate professor and director of Invasive Cardiology Division, Department of Cardiology at the University of Szeged in Hungary.
The Tryton Side Branch Stent System is designed to offer a dedicated strategy for treating atherosclerotic lesions in the side branch at the site of a bifurcation. Tryton’s highly deliverable cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.
Excellent Six-Month Clinical Results
The Tryton Side Branch Stent System demonstrated excellent six-month clinical and angiographic results in a first-in-man study of the system and excellent six-month clinical results from almost 200 patients in four different registries with a rate of target lesion revascularization of less than four percent.
The stent system has received CE Mark approval in Europe and is commercially available in 21 countries throughout Europe and the Middle East. It is not approved in the United States.
About Tryton Medical, Inc.
Tryton Medical, Inc., located in Durham, N.C., is a leading developer of novel stent systems for the treatment of bifurcation lesions. The company was founded in 2003 by Aaron V. Kaplan, M.D. (Professor of Medicine at Dartmouth Medical School/Dartmouth- Hitchcock Medical Center) and Dan Cole to develop stents for the definitive treatment of bifurcation lesions. The Tryton Side Branch Stent System, approved for sale in Europe, is designed to offer a dedicated strategy for treating these challenging cases. Privately held, Tryton is backed by Arnerich Massena & Associates, Spray Ventures, PTV Sciences, and RiverVest Ventures. For more information please visit www.trytonmedical.com.
Source: Tryton Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.